PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling
Abstract
Increased infiltration of T cells into ovarian tumors has been repeatedly shown to be predictive of enhanced patient survival. However, despite the evidence of an active immune response in ovarian cancer (OC), the frequency of responses to immune checkpoint blockade (ICB) therapy in OC is much lower than other cancer types. Recent studies have highlighted that deficiencies in the DNA damage response (DDR) can drive increased genomic instability and tumor immunogenicity, which leads to enhanced responses to ICB. Protein phosphatase 4 (PP4) is a critical regulator of the DDR; however, its potential role in antitumor immunity is currently unknown.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2022
- Source ID
- 10.1136/jitc-2022-005026
Entities
People
- Christopher Wu
- Emma C Utagawa
- Esen Yonca Bassoy
- Kristina A Butler
- Marion Curtis
- Paul M Magtibay
- Remya Raja
- Thomas E Rubino Jr
Organizations
- United States Department of Defense